Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Michael H. Davidson to Drug Therapy, Combination

This is a "connection" page, showing publications Michael H. Davidson has written about Drug Therapy, Combination.

 
Connection Strength
 
 
 
3.873
 
  1. Singh A, Davidson M. Combination therapy with statins: who benefits? Endocrinol Metab Clin North Am. 2014 Dec; 43(4):993-1006.
    View in: PubMed
    Score: 0.453
  2. Davidson MH. Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleve Clin J Med. 2008 Jul; 75(7):479-82, 486-8, 490-1.
    View in: PubMed
    Score: 0.290
  3. McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
    View in: PubMed
    Score: 0.141
  4. Robinson JG, Davidson MH. Can We Cure Atherosclerosis? Rev Cardiovasc Med. 2018; 19(S1):S20-S24.
    View in: PubMed
    Score: 0.140
  5. Benes LB, Bassi NS, Davidson MH. Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. Vasc Health Risk Manag. 2016; 12:481-490.
    View in: PubMed
    Score: 0.130
  6. Davidson MH, Phillips AK, Kling D, Maki KC. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia. Expert Rev Cardiovasc Ther. 2014 Sep; 12(9):1045-54.
    View in: PubMed
    Score: 0.111
  7. Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013 Sep; 35(9):1400-11.e1-3.
    View in: PubMed
    Score: 0.104
  8. Davidson M. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clin Ther. 2013 Aug; 35(8):1247-52.
    View in: PubMed
    Score: 0.103
  9. Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012 Jun; 73(6):e728-34.
    View in: PubMed
    Score: 0.095
  10. Davidson MH. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J Clin Lipidol. 2011 Mar-Apr; 5(2):76-81.
    View in: PubMed
    Score: 0.087
  11. Dembowski E, Davidson MH. Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2009 Apr; 16(2):183-8.
    View in: PubMed
    Score: 0.076
  12. Davidson M. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008 Dec 22; 102(12A):19L-27L.
    View in: PubMed
    Score: 0.075
  13. Davidson MB, Wong A, Hamrahian AH, Stevens M, Siraj ES. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. Endocr Pract. 2008 Nov; 14(8):985-92.
    View in: PubMed
    Score: 0.074
  14. Polonsky TS, Davidson MH. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol. 2008 Apr 17; 101(8A):27B-35B.
    View in: PubMed
    Score: 0.072
  15. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother. 2007 Oct; 8(15):2569-78.
    View in: PubMed
    Score: 0.069
  16. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007 Jul; 29(7):1354-67.
    View in: PubMed
    Score: 0.068
  17. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol. 2007 May 01; 49(17):1753-62.
    View in: PubMed
    Score: 0.067
  18. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007 Mar 19; 99(6A):3C-18C.
    View in: PubMed
    Score: 0.065
  19. Robinson JG, Davidson MH. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther. 2006 Jul; 4(4):461-76.
    View in: PubMed
    Score: 0.063
  20. Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, Davidson MH. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006 Apr 17; 97(8A):61C-68C.
    View in: PubMed
    Score: 0.061
  21. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 Jan; 5(1):145-56.
    View in: PubMed
    Score: 0.061
  22. Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005 Nov 07; 96(9A):3K-13K; discussion 34K-35K.
    View in: PubMed
    Score: 0.060
  23. Bays H, McKenney J, Davidson M. Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther. 2005 Sep; 3(5):789-820.
    View in: PubMed
    Score: 0.060
  24. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005 Jan 01; 95(1):120-2.
    View in: PubMed
    Score: 0.057
  25. Toth PP, Davidson MH. Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother. 2005 Jan; 6(1):131-9.
    View in: PubMed
    Score: 0.057
  26. Davidson MH, Toth PP. Combination therapy in the management of complex dyslipidemias. Curr Opin Lipidol. 2004 Aug; 15(4):423-31.
    View in: PubMed
    Score: 0.055
  27. Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L, Strony J, Suresh R, Veltri E. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
    View in: PubMed
    Score: 0.055
  28. Davidson MH. Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. Curr Atheroscler Rep. 2003 Sep; 5(5):418-22.
    View in: PubMed
    Score: 0.052
  29. Davidson MH. Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. J Am Coll Cardiol. 2003 Jul 16; 42(2):398-9; author reply 399.
    View in: PubMed
    Score: 0.051
  30. Davidson MH. Combination lipid-lowering therapy in diabetes. Curr Diab Rep. 2003 Jun; 3(3):263-8.
    View in: PubMed
    Score: 0.051
  31. Davidson MH. Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther. 2003 May; 1(1):11-21.
    View in: PubMed
    Score: 0.051
  32. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002 Dec 18; 40(12):2125-34.
    View in: PubMed
    Score: 0.049
  33. Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol. 2002 Nov 20; 90(10B):50K-60K.
    View in: PubMed
    Score: 0.049
  34. Davidson M, Min YI, Holbrook JT, Van Natta M, Quinn TC, Murphy RL, Welch W, Jabs DA, Meinert CL. Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. J Infect Dis. 2002 Oct 01; 186(7):1013-8.
    View in: PubMed
    Score: 0.048
  35. Davidson MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002 Jan; 11(1):125-41.
    View in: PubMed
    Score: 0.046
  36. Davidson MH, Maki KC, Karp SK, Ingram KA. Management of hypercholesterolaemia in postmenopausal women. Drugs Aging. 2002; 19(3):169-78.
    View in: PubMed
    Score: 0.046
  37. Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, Donovan JM, Burke SK. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001 Jun; 24(6):467-74.
    View in: PubMed
    Score: 0.044
  38. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, Donovan JM, Burke SK, Davidson MH. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001 Apr 01; 110(5):352-60.
    View in: PubMed
    Score: 0.044
  39. Davidson MH. Statin trials in progress: unanswered questions. Curr Atheroscler Rep. 2001 Jan; 3(1):9-13.
    View in: PubMed
    Score: 0.043
  40. Davidson M. Long-term safety of risperidone. J Clin Psychiatry. 2001; 62 Suppl 21:26-8.
    View in: PubMed
    Score: 0.043
  41. Weiser M, Levi L, Zamora D, Biegon A, SanGiovanni JP, Davidson M, Burshtein S, Gonen I, Radu P, Slobozean Pavalache K, Nastas I, Hemi R, Ryan T, Davis JM. Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial. JAMA Psychiatry. 2019 10 01; 76(10):1009-1017.
    View in: PubMed
    Score: 0.040
  42. Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
    View in: PubMed
    Score: 0.039
  43. Davidson MH, Macariola-Coad JR, McDonald AM, Maki KC, Hall HA. Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol. 1997 Sep 15; 80(6):797-8.
    View in: PubMed
    Score: 0.034
  44. Stern RG, Schmeidler J, Davidson M. Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry. 1997 Jul 15; 42(2):138-43.
    View in: PubMed
    Score: 0.034
  45. Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, Correll CU. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013 Nov; 39(6):1230-41.
    View in: PubMed
    Score: 0.026
  46. Ferdinand KC, Davidson MH, Kelly MT, Setze CM. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Am J Cardiovasc Drugs. 2012 Apr 01; 12(2):117-25.
    View in: PubMed
    Score: 0.024
  47. Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44.
    View in: PubMed
    Score: 0.023
  48. Chen F, Maccubbin D, Yan L, Sirah W, Chen E, Sisk CM, Davidson M, Blomqvist P, McKenney JM. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol. 2013 Jul 15; 167(1):225-31.
    View in: PubMed
    Score: 0.023
  49. Ballantyne CM, Davidson MH, Setze CM, Kelly MT. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu. J Clin Lipidol. 2011 Sep-Oct; 5(5):401-7.
    View in: PubMed
    Score: 0.022
  50. Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, Jones-Burton C. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011 Aug 15; 108(4):523-30.
    View in: PubMed
    Score: 0.022
  51. Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010 May 15; 105(10):1409-12.
    View in: PubMed
    Score: 0.020
  52. Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010; 10(2):73-84.
    View in: PubMed
    Score: 0.020
  53. Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 01; 104(1):74-81.
    View in: PubMed
    Score: 0.019
  54. Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009 May; 204(1):208-15.
    View in: PubMed
    Score: 0.018
  55. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008 May 15; 101(10):1428-36.
    View in: PubMed
    Score: 0.018
  56. Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008; 28(10):625-34.
    View in: PubMed
    Score: 0.018
  57. Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, Ballantyne CM. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 01; 101(5):625-30.
    View in: PubMed
    Score: 0.017
  58. Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther. 2006 Jun; 28(6):849-59.
    View in: PubMed
    Score: 0.016
  59. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006 Apr 15; 97(8):1198-205.
    View in: PubMed
    Score: 0.015
  60. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002 Dec 03; 137(11):875-83.
    View in: PubMed
    Score: 0.012
  61. Harris ST, Eriksen EF, Davidson M, Ettinger MP, Moffett AH, Baylink DJ, Crusan CE, Chines AA. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2001 05; 86(5):1890-7.
    View in: PubMed
    Score: 0.011
  62. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000 Feb; 85(2):720-6.
    View in: PubMed
    Score: 0.010
  63. Schrott HG, Stein EA, Dujovne CA, Davidson MH, Goris GB, Oliphant TH, Phillips JC, Shawaryn GG. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol. 1995 Jan 01; 75(1):34-9.
    View in: PubMed
    Score: 0.007
  64. Bierer LM, Aisen PS, Davidson M, Ryan TM, Schmeidler J, Davis KL. A pilot study of clonidine plus physostigmine in Alzheimer's disease. Dementia. 1994 Sep-Oct; 5(5):243-6.
    View in: PubMed
    Score: 0.007
  65. Bierer LM, Aisen PS, Davidson M, Ryan TM, Stern RG, Schmeidler J, Davis KL. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 1993; 7(2):98-104.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.